| Literature DB >> 23819679 |
Kimihide Kusafuka1, Tomoko Miki, Takashi Nakajima.
Abstract
BACKGROUND: The early phase of salivary gland carcinomas with high-grade transformation (HGT) is extremely rare. We reported one case of adenoid cystic carcinoma (AdCC) with early HGT, herein. CASEEntities:
Mesh:
Substances:
Year: 2013 PMID: 23819679 PMCID: PMC3737055 DOI: 10.1186/1746-1596-8-113
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Figure 1Magnetic resonance imaging (T2 weight imaging) showed an irregularly lobulated mass with irregularly low-intensity and partly high-intensity (white arrows) in the left parotid gland.
Figure 2Macroscopically, the tumor showed an ill-defined mass, and a nodular focus (arrows) in the main lesion (white dotted lines are the sectioning lines). The nodular focus was comparable to the HGT component.
Figure 3Histological findings of the present case. A high-grade carcinoma (black dotted line), which was different from the adenoid cystic carcinoma (AdCC) component (blue line), was seen in the central area of this tumor (A: whole mount H&E stain section). A focus of high-grade carcinoma (asterisk) was well demarcated in typical AdCC area and no gradual transition zone was seen (black dotted line) (B: H&E stain x20). Typical of AdCC showed a cribriform pattern (C: H&E stain x200). Solid subtype of AdCC was seen partly (arrow shows cribriform pattern within the solid subtype of AdCC.) (D: H&E stain x200). High-grade carcinoma showed solid and insular growth (E: H&E stain x200) with clear cytoplasm and marked nuclear atypia (F: H&E stain x400).
The antibodies used in this study and their results
| | | | |||
|---|---|---|---|---|---|
| EMA | E29 | DakoCytomation (Carpinteria, CA, USA) | + | + | ++ |
| GCDFP-15 | NCL-GCDFP15 | Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) | - | - | - |
| Her-2 | | DakoCytomation (Carpinteria CA) | - | 1+ | 3+ |
| EGFR | NCL-L-EGFR | Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) | - | - | - |
| AR | AR441 | DakoCytomation (Carpinteria, CA, USA) | - | - | - |
| CK5/6 | D5/16 B4 | DakoCytomation (Carpinteria, CA, USA) | + | + | -(myo+) |
| S-100 | | DakoCytomation (Carpinteria, CA, USA) | + | + | - |
| ASMA | 1A4 | DakoCytomation (Carpinteria, CA, USA) | ++ | + | - |
| calponin | CALP | DakoCytomation (Carpinteria, CA, USA) | + | f+ | - |
| CK14 | LL002 | Chemicon International (Temecula, CA, USA) | + | p+ | -(myo+) |
| p63 | 4A4 | Lab Vision (Fremont, CA, USA) | ++ | p+ | -(myo+) |
| mammaglobin | 304-1A5 | DakoCytomation (Carpinteria, CA, USA) | - | f+ | |
| p53 | DO-7 | DakoCytomation (Carpinteria, CA, USA) | f+ | p+ | ++ |
| cyclin A | NCL-CYCLN A | Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) | 10.3% | 17.3% | 34.5% |
| cyclin B1 | NCL-CYCLN B1 | Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) | 0.5% | 12.2% | 50.3% |
| cyclin D1 | DSC-6 | DakoCytomation (Carpinteria CA, USA) | - | 1.1% | - |
| cylcin E | NCL-CYCLN E | Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) | - | - | - |
| p16 | G175-405 | BD Biosciences (Franklin Lakes, NJ, USA) | f+ | p+ | ++ |
| MDM2 | SMP14 | Themo Fisher Scientific (Cheshire, UK) | - | - | - |
| Ki-67L.I. | MIB-1 | DakoCytomation (Carpinteria, CA, USA) | 34.5% | 49.7% | 73.2% |
ACC, adenoid cystic carcinoma area; HGT, high-grade transformation area.
EMA, epithelial membrane antigen; GCDFP-15, gross cystic disease fluid protein-15; EGFR. Epidermal growth factor receptor; AR, androgen receptor; CK, cytokeratin; ASMA, alpha-smooth muscle actin.
—, negative; f+, focally positive (1-9%); p+, partially positive (10-19%); +, positive (20-60%); ++, diffusely positive (>60%); myo, myoepithelial cells.
Figure 4The immuno-phenotypes of high-grade carcinoma, comparing with those of typical AdCC. The high-grade carcinoma component showed strong and diffuse positivity for EMA (A: immunostaining x200), whereas the typical AdCC component showed limited positivity forthe true lumens in the cribriform growth area (B: immunostaining x200). The high-grade carcinoma component was negative for ASMA (C: immunostainng x200: the blood vessels were positive), whereas the peripheral cells adjacent the pseudocysts in the AdCC area were positive for ASMA (D: immunostaining x200). The high-grade carcinoma component was negative for p63 (E: immnostaining x200: the involved myoepithelial cells were positive), whereas the peripheral cells adjacent the pseudocysts in typical AdCC area were positive for p63 (F: immunostaining x200).
Figure 5Results of the immunohistochemical examination of high-grade carcinoma component in the present case. Typical AdCC area showed low labeling index for Ki-67, whereas the high-grade carcinoma component (asterisk) showed a high Ki-67 labeling index (A: immunostaining x20). The high-grade carcinoma component also showed strong and diffuse positivity for p53 (B: immunostaining x200: inset; weakly positive for p53 in typical AdCC), Her-2 (C; inset; weakly positive for Her-2 in typical AdCC: immunostaining x400), p16 (D: immunostaining x200: inset; focally positivity for p16 in typical AdCC; immunostaining x400), and cyclin A (E; immunostaining x200: inset; focally positivity for cyclin A in typical AdCC; immunostaining x400), respectively.